Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Brigitte Uebelhart"'
Autor:
Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A. Bischoff-Ferrari, Diana Frey, Reto W. Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari
Publikováno v:
Swiss Medical Weekly, Vol 147, Iss 3334 (2017)
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are starte
Externí odkaz:
https://doaj.org/article/560071dde1f44e5a8dccbd40b76f1383
Autor:
Brigitte Uebelhart, Serge Ferrari
Publikováno v:
Revue Médicale Suisse. 17:784-787
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::173425ed932a6d07d55340a224c73ee7
https://doi.org/10.53738/revmed.2021.17.735.0784
https://doi.org/10.53738/revmed.2021.17.735.0784
Autor:
Sigrid Jehle-Kunz, Hans-Jörg Häuselmann, Mitra Keschawarzi, Olivier Lamy, Franck Luzuy, Natalie Marcoli, Christian Meier, Brigitte Uebelhart, Peter Wiedersheim
Publikováno v:
Healthcare; Volume 10; Issue 2; Pages: 295
Osteoporosis is the most common chronic metabolic bone disease, known to be underdiagnosed and undertreated in parts of the Swiss population. Due to expected rise in new fragility fractures, adequate awareness of associated risk factors and diagnosti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c196b348c98b9e264b9150977bad85f
Autor:
Serge Ferrari, Robin Peter, Kuntheavy Ing Lorenzini, Marie-Claude Audet, Marina Portela, Marie-Josée Bégin, Thierry Chevalley, Ivan Padlina, Brigitte Uebelhart, Didier Hannouche, René Rizzoli, Emmanuel Biver, Raphael P. H. Meier
Publikováno v:
Journal of bone and mineral research, Vol. 37, No 1 (2022) pp. 87-94
Atypical femoral fractures (AFFs) occurring during the course of osteoporosis treatment usually lead to discontinuation of anti-resorptive (AR) drugs. However, the risk of fracture after an AFF is unknown. We conducted a follow-up study of patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa6dfd25a8d03d85574a4c857ef0b845
https://archive-ouverte.unige.ch/unige:158270
https://archive-ouverte.unige.ch/unige:158270
Autor:
null Marie‐Josée Bégin, null Marie‐Claude Audet, null Thierry Chevalley, null Marina Portela, null Ivan Padlina, null Didier Hannouche, null Kuntheavy Ing Lorenzini, null Raphaël Meier, null Robin Peter, null Brigitte Uebelhart, null René Rizzoli, null Serge Ferrari, null Emmanuel Biver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f47b6c9790a747b80cca72a57e4f5f4
https://doi.org/10.1002/jbmr.4461/v2/response1
https://doi.org/10.1002/jbmr.4461/v2/response1
Autor:
Brigitte, Uebelhart, Serge, Ferrari
Publikováno v:
Revue medicale suisse. 17(735)
Romosozumab is a monoclonal antibody against sclerostin. Its dual effect on bone is to increase formation and decrease resorption. Sub-cutaneous injections of romosozumab are administered monthly for one year and must be relayed with a bone resorptio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9bead83e29db80cb2037bb358045f9d8
https://pubmed.ncbi.nlm.nih.gov/33881241
https://pubmed.ncbi.nlm.nih.gov/33881241
Publikováno v:
Revue medicale suisse. 17(720-1)
New recommendations from the Swiss Association against Osteoporosis (SVGO) concerning fracture risk stratification and treatment delineate two new risk categories : very high risk (FRAX 10-years probability of fracture at least 20 % above the usual i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e10d31004e18cf22497a6ccc8f5135e
https://pubmed.ncbi.nlm.nih.gov/33443834
https://pubmed.ncbi.nlm.nih.gov/33443834
Autor:
Brigitte Uebelhart, Serge Ferrari
Publikováno v:
Revue Médicale Suisse. 14:70-73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fa187b566e676d8b77b70382093a416
https://doi.org/10.53738/revmed.2018.14.588-89.0070
https://doi.org/10.53738/revmed.2018.14.588-89.0070
Autor:
Elena, Gonzalez Rodriguez, Olivier, Lamy, Bérengère, Aubry-Rozier, Delphine, Stoll, Brigitte, Uebelhart
Publikováno v:
Revue medicale suisse. 15(647)
Denosumab discontinuation is associated with a severe rebound effect combining elevation of bone remodeling markers for two years and loss of the gained bone density. In the absence of a potent bisphosphonate prescription at denosumab discontinuation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ae30c65573021d62f9f2837bd346b77b
https://pubmed.ncbi.nlm.nih.gov/30994986
https://pubmed.ncbi.nlm.nih.gov/30994986
Autor:
Brigitte, Uebelhart, Olivier, Lamy
Publikováno v:
Revue medicale suisse. 15(647)
Irrespective of their age, patients with recent fragility fracture have an increased risk of recurrence : this is the imminent fracture risk of multiple origins. As well the vertebral than the non-vertebral fractures are equally predictive of an incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59e37742db069779cedf10543969b1b5
https://pubmed.ncbi.nlm.nih.gov/30994984
https://pubmed.ncbi.nlm.nih.gov/30994984